STOCKIQ
Global Intelligence Terminal
Loading live prices…
LIVE
--:--:--
AI-generated, informational and educational only. Not financial advice. Past performance does not indicate future results. Always do your own research.

Moderna Inc (MRNA)

A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.

Biotechnology· US· www.modernatx.com
Trade MRNA on Webull
14/100
Low signalSIGNAL SCORE
P(beat S&P 500 · next 20 sessions)46%

Our last 30 days of resolved calls came true 29% of the time.See the track record →

Price
$145.62
1 day
+1.29%
1 week
+6.02%
1 month
+2.44%
1 year
+502.05%
Market cap
$57.4B
Company fundamentals
EPS (TTM)
$-7.98
Debt / Equity
0.09
Current ratio
2.29
Operating margin
-149.0%
Net margin
-141.4%
Gross margin
36.4%
Return on equity
-39.2%
Revenue growth (YoY)
-27.6%

Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.

Example trade plan · illustrative risk framework
Entry zone
$143.44$148.53
Stop-loss (exit)
$131.06 −10%
Target (exit)
$174.74 +20%

A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.

Why it ranks: factor attribution

Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →

Why it's moving: recent catalysts

🤖 The dominant catalyst here is **none** — the headlines are a mix of comparative analyst commentary, sector-wide mRNA sentiment, and adjacent healthcare news rather than a company-specific event like an earnings beat, product approval, or deal. Continuation likelihood is therefore low-to-moderate and largely headline-driven, with maybe a 30–40% probability that any near-term move persists over the next few weeks absent a fresh MRNA-specific catalyst. Informational only — not financial advice.

Any AI summary is an interpretation of public news, not advice or a price target.